<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39315545</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2379-3708</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>JCI insight</Title><ISOAbbreviation>JCI Insight</ISOAbbreviation></Journal><ArticleTitle>An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e180784</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/jci.insight.180784</ELocationID><Abstract><AbstractText>BACKGROUNDThe level of nasal spike-specific secretory IgA (sIgA) is inversely correlated with the risk of SARS-CoV-2 Omicron infection. This study aimed to evaluate the safety and immunogenicity of intranasal vaccination using Ad5-S-Omicron (NB2155), a replication-incompetent human type 5 adenovirus carrying Omicron BA.1 spike.METHODSAn open-label, single-center, investigator-initiated trial was carried out on 128 health care workers who had never been infected with SARS-CoV-2 and had previously received 2 or 3 injections of inactivated whole-virus vaccines, with the last dose given 3-19 months previously (median 387 days, IQR 333-404 days). Participants received 2 intranasal sprays of NB2155 at 28-day intervals between November 30 and December 30, 2022. Safety was evaluated by solicited adverse events and laboratory tests. The elevation of nasal mucosal spike-specific sIgA and serum neutralizing activities were assessed. All participants were monitored for infection by antigen tests, disease symptoms, and the elevation of nucleocapsid-specific sIgA in the nasal passage.RESULTSThe vaccine-related solicited adverse events were mild. Nasal spike-specific sIgA against 10 strains had a mean geometric mean fold increase of 4.5 after the first dose, but it increased much higher to 51.5 after the second dose. Serum neutralizing titers also increased modestly to 128.1 (95% CI 74.4-220.4) against authentic BA.1 and 76.9 (95% CI 45.4-130.2) against BA.5 at 14 days after the second dose. Due to the lifting of the zero-COVID policy in China on December 7, 2022, 57.3% of participants were infected with BA.5 between days 15 and 28 after the first dose, whereas no participants reported having any symptomatic infections between day 3 and day 90 after the second dose. The elevation of nasal nucleocapsid-specific sIgA on days 0, 14, 42, and 118 after the first dose was assessed to verify that these 2-dose participants had no asymptomatic infections.CONCLUSIONA 2-dose intranasal vaccination regimen using NB2155 was safe, was well tolerated, and could dramatically induce broad-spectrum spike-specific sIgA in the nasal passage. Preliminary data suggested that the intranasal vaccination may establish an effective mucosal immune barrier against infection and warranted further clinical studies.TRIAL REGISTRATIONChinese Clinical Trial Registry (ChiCTR2300070346).FUNDINGNatural Science Foundation of China, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Baoqing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Peiyan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Xuefeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Weijie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Si</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yijun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Zhangkai J</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yongmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Drug Clinical Study, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xinke</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Drug Clinical Study, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Trial Institution Clinical Research Ward, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Guangzhou Bio-Island Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhongfang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Bio-Island Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Nanshan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou National Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000068397">Clinical Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCI Insight</MedlineTA><NlmUniqueID>101676073</NlmUniqueID><ISSNLinking>2379-3708</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007071">Immunoglobulin A, Secretory</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="Y">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007071" MajorTopicYN="Y">Immunoglobulin A, Secretory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009297" MajorTopicYN="N">Nasal Mucosa</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adaptive immunity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39315545</ArticleId><ArticleId IdType="pmc">PMC11457852</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.180784</ArticleId><ArticleId IdType="pii">180784</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singanayagam A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183–195. doi: 10.1016/S1473-3099(21)00648-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00648-4</ArticleId><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation> Our World in Data. Coronavirus (COVID-19) Vaccinations.  https://ourworldindata.org/covid-vaccinations Updated August 9, 2024. Accessed August 10, 2024.</Citation></Reference><Reference><Citation>Klaassen F, et al. Changes in population immunity against infection and severe disease from severe acute respiratory syndrome coronavirus 2 Omicron variants in the United States between December 2021 and November 2022. Clin Infect Dis. 2023;77(3):355–361. doi: 10.1093/cid/ciad210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad210</ArticleId><ArticleId IdType="pmc">PMC10425195</ArticleId><ArticleId IdType="pubmed">37074868</ArticleId></ArticleIdList></Reference><Reference><Citation> World Health Organization. Global COVID-19 Vaccination Strategy in a Changing World: July 2022 update.  https://www.who.int/publications/m/item/global-covid-19-vaccination-strategy-in-a-changing-world--july-2022-update Updated July 22, 2022. Accessed August 10, 2024.</Citation></Reference><Reference><Citation>Hui KPY, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603(7902):715–720. doi: 10.1038/s41586-022-04479-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04479-6</ArticleId><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 Omicron infection. N Engl J Med. 2022;387(14):1333–1336. doi: 10.1056/NEJMc2209651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209651</ArticleId><ArticleId IdType="pmc">PMC9511632</ArticleId><ArticleId IdType="pubmed">36103621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo F, et al. Mucosal IgA against SARS-CoV-2 Omicron infection. N Engl J Med. 2022;387(21):e55.</Citation><ArticleIdList><ArticleId IdType="pubmed">36416778</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking U, et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect Dis. 2023;23(2):150–152. doi: 10.1016/S1473-3099(22)00834-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00834-9</ArticleId><ArticleId IdType="pmc">PMC9833832</ArticleId><ArticleId IdType="pubmed">36640796</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabst R. Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-structure, function and species differences. Vaccine. 2015;33(36):4406–4413. doi: 10.1016/j.vaccine.2015.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.07.022</ArticleId><ArticleId IdType="pubmed">26196324</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang R, et al. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir Med. 2023;11(7):613–623. doi: 10.1016/S2213-2600(23)00049-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00049-8</ArticleId><ArticleId IdType="pmc">PMC9991083</ArticleId><ArticleId IdType="pubmed">36898400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897. doi: 10.1016/S0140-6736(20)31866-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31866-3</ArticleId><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854. doi: 10.1016/S0140-6736(20)31208-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31208-3</ArticleId><ArticleId IdType="pmc">PMC7255193</ArticleId><ArticleId IdType="pubmed">32450106</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385(25):2348–2360. doi: 10.1056/NEJMoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe WP, et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med. 1953;84(3):570–573. doi: 10.3181/00379727-84-20714.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-84-20714</ArticleId><ArticleId IdType="pubmed">13134217</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020;11(1):4207. doi: 10.1038/s41467-020-18077-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18077-5</ArticleId><ArticleId IdType="pmc">PMC7442803</ArticleId><ArticleId IdType="pubmed">32826924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, et al. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants. Signal Transduct Target Ther. 2023;8(1):167. doi: 10.1038/s41392-023-01423-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01423-6</ArticleId><ArticleId IdType="pmc">PMC10106878</ArticleId><ArticleId IdType="pubmed">37069171</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, et al. Infection rate in Guangzhou after easing the zero-COVID policy: seroprevalence results to ORF8 antigen. Lancet Infect Dis. 2023;23(4):403–404. doi: 10.1016/S1473-3099(23)00112-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00112-3</ArticleId><ArticleId IdType="pubmed">36803917</ArticleId></ArticleIdList></Reference><Reference><Citation> Guangzhou Municipal Health Commission. Guangzhou: The infection rate has now over 85%.  https://www.cnr.cn/gd/guangdongyaowen/20230118/t20230118_526130010.shtml Updated January 18, 2023. Accessed August 23, 2024.</Citation></Reference><Reference><Citation>Liew F, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine. 2023;87:104402. doi: 10.1016/j.ebiom.2022.104402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104402</ArticleId><ArticleId IdType="pmc">PMC9762734</ArticleId><ArticleId IdType="pubmed">36543718</ArticleId></ArticleIdList></Reference><Reference><Citation>Roubidoux EK, et al. Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2. Sci Rep. 2023;13(1):17820. doi: 10.1038/s41598-023-44989-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-44989-5</ArticleId><ArticleId IdType="pmc">PMC10587113</ArticleId><ArticleId IdType="pubmed">37857783</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler SE, et al. Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals. Front Immunol. 2020;11:618685. doi: 10.3389/fimmu.2020.618685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.618685</ArticleId><ArticleId IdType="pmc">PMC7876222</ArticleId><ArticleId IdType="pubmed">33584712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022;10(8):749–760. doi: 10.1016/S2213-2600(22)00131-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00131-X</ArticleId><ArticleId IdType="pmc">PMC9135375</ArticleId><ArticleId IdType="pubmed">35644168</ArticleId></ArticleIdList></Reference><Reference><Citation>Treanor JJ, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999;18(9–10):899–906. doi: 10.1016/S0264-410X(99)00334-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(99)00334-5</ArticleId><ArticleId IdType="pubmed">10580204</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhavan M, et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial. EBioMedicine. 2022;85:104298. doi: 10.1016/j.ebiom.2022.104298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104298</ArticleId><ArticleId IdType="pmc">PMC9550199</ArticleId><ArticleId IdType="pubmed">36229342</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh C, et al. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin) NPJ Vaccines. 2023;8(1):125. doi: 10.1038/s41541-023-00717-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00717-8</ArticleId><ArticleId IdType="pmc">PMC10439197</ArticleId><ArticleId IdType="pubmed">37596281</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicks MD, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 2012;7(7):e40385. doi: 10.1371/journal.pone.0040385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0040385</ArticleId><ArticleId IdType="pmc">PMC3396660</ArticleId><ArticleId IdType="pubmed">22808149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull RN, et al. New viral agents recovered from tissue cultures of monkey kidney cells. I. Origin and properties of cytopathogenic agents S.V.1, S.V.2, S.V.4, S.V.5, S.V.6, S.V.11, S.V.12 and S.V.15. Am J Hyg. 1956;63(2):204–215.</Citation><ArticleIdList><ArticleId IdType="pubmed">13302209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasker S, et al. Safety and immunogenicity of a novel intranasal influenza vaccine (NasoVAX): a phase 2 randomized, controlled trial. Vaccines (Basel) 2021;9(3):224. doi: 10.3390/vaccines9030224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030224</ArticleId><ArticleId IdType="pmc">PMC8000446</ArticleId><ArticleId IdType="pubmed">33807649</ArticleId></ArticleIdList></Reference><Reference><Citation>Minozzi S, et al. Comparative efficacy and safety of vaccines to prevent seasonal influenza: a systematic review and network meta-analysis. EClinicalMedicine. 2022;46:101331. doi: 10.1016/j.eclinm.2022.101331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101331</ArticleId><ArticleId IdType="pmc">PMC8961170</ArticleId><ArticleId IdType="pubmed">35360146</ArticleId></ArticleIdList></Reference><Reference><Citation>Barria MI, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis. 2013;207(1):115–124. doi: 10.1093/infdis/jis641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis641</ArticleId><ArticleId IdType="pmc">PMC3571238</ArticleId><ArticleId IdType="pubmed">23087433</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterlin D, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577):eabd2223. doi: 10.1126/scitranslmed.abd2223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd2223</ArticleId><ArticleId IdType="pmc">PMC7857408</ArticleId><ArticleId IdType="pubmed">33288662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo F, et al. Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86. Lancet Infect Dis. 2024;24(1):e7–e9. doi: 10.1016/S1473-3099(23)00732-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00732-6</ArticleId><ArticleId IdType="pubmed">38071989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies. Signal Transduct Target Ther. 2024;9(1):190. doi: 10.1038/s41392-024-01906-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01906-0</ArticleId><ArticleId IdType="pmc">PMC11263566</ArticleId><ArticleId IdType="pubmed">39039046</ArticleId></ArticleIdList></Reference><Reference><Citation> Chinese Center for Disease Control and Prevention. National coronavirus infection situation.  https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202301/t20230125_263519.html Updated January 25, 2023. Accessed August 10, 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>